Navigation Links
AHIP Statement on H.R. 4626
Date:2/24/2010

Karen Ignagni, President and CEO of America's Health Insurance Plans (AHIP), released the following statement today on H.R. 4626

Washington, DC (Vocus) February 24, 2010 -- Karen Ignagni, President and CEO of America's Health Insurance Plans (AHIP), released the following statement today on H.R. 4626:

“In attempting to solve a problem that doesn’t exist, this legislation is the triumph of sound bites over substance. The Congressional Budget Office has said that passage of this legislation will do nothing to reduce health care costs. Moreover, according to the National Association of Insurance Commissioners, anti-competitive ‘activities are not permitted under the McCarran-Ferguson Act and are not tolerated under state law.’ Real reform means containing costs to ensure that health care is affordable for working families and small businesses. It’s time to clear the political hurdles that stand in the way of real cost containment.”

Additional information on the McCarran Ferguson Act

New AHIP Letter: Last week, AHIP sent a letter to Capitol Hill, which states: “The claim that McCarran-Ferguson allows insurers to engage in practices such as price fixing, market allocation, and bid rigging is incorrect and the types of activities the legislation proposes to address already are subject to federal and state antitrust laws.”

National Association of Insurance Commissioners letter (10/21/2009): “The potential for bid rigging, price fixing and market allocation is of great concern to state insurance regulators and we share your view that such practices are harmful to consumers and cannot be tolerated. However, we want to assure you that these activities are not permitted under the McCarran-Ferguson Act and are not tolerated under state law. Indeed, state insurance regulators actively enforce prohibitions in these areas.”

Congressional Budget Office analysis (10/29/09): “The analysis also takes into account the provisions of section 262 of Division A regarding the application of federal antitrust laws to health insurers. CBO estimates that implementing those provisions would have no significant effects on either the federal budget or the premiums that private insurers charged for health insurance.”

Congressional Research Service analysis (8/31/2009): “Given the courts’ narrowing definition of the ‘business of insurance,’ they would not be likely, in any event, to find such activities as market allocation, tying, or monopolization protected by McCarran-Ferguson from the application of the antitrust laws.”

What Others Are Saying About McCarran-Ferguson:

Los Angeles Times: “Lawmakers are expected to pass a bill this week that would repeal the federal antitrust exemption that insurance companies have enjoyed since 1945 -- a move that makes for little more than a good sound bite…Removing the exemption won't do much to boost competition or spark a price war among insurers, however. (The Congressional Budget Office said that a similar proposal in the House's comprehensive healthcare bill would have no significant effect on premiums because state regulators already require insurers to price their coverage competitively.)” (Los Angeles Times, Back to the drawing board, 02/08/2010)

Paul Ginsburg, Center for Studying Health System Change: “‘I don't think this will have much effect. This is strictly political posturing.’…In fact, Ginsburg said, insurers already are prohibited from colluding to raise prices and from merging at will. They can, however, pool information about risks, and it can be argued that that helps them manage ways of controlling costs and even rates.” (McClatchy, Analysts: Stripping health insurers' antitrust protection won't affect consumers much, 02/07/2010)

Kaiser Health News: “…many antitrust experts say that ending the exemption -- by repealing the 1945 McCarran-Ferguson Act -- wouldn't significantly increase competition or reduce premiums.” (Kaiser Health News, The Antitrust Exemption For Health Insurers: Meaningful Or Not?, 02/08/2010)
Scott Harrington: “It might sound good, but I can think of very few things in the bill that would be
less consequential for consumers of health insurance.” (Kaiser Health News, The Antitrust Exemption For Health Insurers: Meaningful Or Not?, 02/08/2010)

CQ: “…bill supporters have little evidence to support claims that the antitrust exemption leads to higher costs. In fact, their statements in support of the bill sometimes suggest the opposite.” (CQ, House Democrats Push Bill to Eliminate Insurance Antitrust Exemption, 02/05/2010)

Ezra Klein: “On the other hand, since it doesn't matter much, and it's good politics either way, Democrats may as well go after it. They just shouldn't fool themselves into thinking they've actually done anything useful when they've finished.” (The Washington Post, Ezra Klein, A primer on the antitrust exemption for insurers, 02/08/2010)

Contact:
Robert Zirkelbach
202-778-8493

###

Read the full story at http://www.prweb.com/releases/AHIP_Statement/HR_4626/prweb3649054.htm.


'/>"/>
Source: PRWeb
Copyright©2010 Vocus, Inc.
All rights reserved  

Related medicine news :

1. Court Orders Reinstatement of Vital, Cost-Saving Treatment for Children With Autism
2. Catholic Health Association Statement on February 25 Health Reform Summit
3. AHIP Statement on the Status of Health Care Reform
4. Statement from Larry Minnix, President & CEO, American Association of Homes and Services for the Aging, on President Obamas Health Care Reform Proposal
5. Pelosi Statement on President Obamas Health Insurance Reform Proposal
6. Pelosi Statement on Additional Aid to States In Medicare Part D Payments
7. Statement from Lawrence Massa, CEO and President, Minnesota Hospital Association
8. China Cord Blood Corporation Warrant Registration Statement Declared Effective by SEC
9. PolicyLink CEO Angela Glover Blackwell Released the Following Statement on First Lady Michelle Obamas Childhood Obesity Initiative
10. AHIP Statement on New Health Spending Projections
11. Statement From IHA President Maryjane A. Wurth on Illinois Supreme Court Medical Liability Ruling
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
AHIP Statement on H.R. 4626 
(Date:1/17/2017)... ... January 17, 2017 , ... ... companies and ranked among the top US security companies for consecutive years, today ... This announcement brings a year-long independent board nomination process to a close and ...
(Date:1/17/2017)... (PRWEB) , ... January 17, 2017 , ... ... Center and the Montclair State University’s Athletic Training Education program forged a relationship ... Athletic Training Education Program, which is consists of both student members and ...
(Date:1/16/2017)... ... ... California Southern University has named Dr. Steven Beazley University President. ... a core faculty member, teaching master’s and doctoral courses in the university’s School of ... where he earned his Doctor of Psychology degree in 1998. Dr. Beazley also has ...
(Date:1/16/2017)... ... January 16, 2017 , ... With the Grand Opening Event planned for ... use by sports teams and the general public. Built in five months by Centerpoint, ... be converted into basketball or pickleball courts. The space is also suitable for indoor ...
(Date:1/16/2017)... ... January 16, 2017 , ... As New York’s ... Victor Giamos, MD to their medical staff, according to eye surgeon, Jeffrey Martin, ... Eye Care, a division of SightMD. Dr. Giamos will practice primarily out of ...
Breaking Medicine News(10 mins):
(Date:1/17/2017)... Calif. and KANSAS CITY, ... Children,s Hospitals Neonatal Consortium (CHNC) has selected Velos ... their visionary data management and multicenter initiatives. ... organization comprised of 32 Neonatal Intensive Care Units ... America . The consortium provides a benchmark ...
(Date:1/17/2017)... , Jan. 17, 2016  Attorney Advertising -- Bronstein, Gewirtz ... purchasers of Anthera Pharmaceuticals, Inc. ("Anthera" or the "Company") (NASDAQ: ... additional information and assist the investigation by visiting the firm,s ... Anthera and certain of its officers and/or directors have violated ... 1934. ...
(Date:1/17/2017)...   Tocagen Inc ., a clinical-stage, cancer-selective gene therapy company, ... research and pharmaceutical development at Tocagen, will present at Phacilitate ... 17-20 in Miami . Details ... ... replicating viruses - what to do when and why Date and ...
Breaking Medicine Technology: